COMPAZINE
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Oct 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPAZINE (prochlorperazine) is an oral extended-release capsule small molecule antipsychotic and antiemetic approved in 1999. The generic mechanism involves dopamine antagonism in the central nervous system. It is primarily used for nausea, vomiting, and psychotic disorders across multiple patient populations.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), likely transitioning to smaller maintenance-focused teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on COMPAZINE offers limited career growth opportunity given LOE-approaching status and zero linked job postings. Positions on this product are typically focused on legacy management, defending market share, and transitioning to generic/authorized generic strategies rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.